Toward effective long-term prevention of thromboembolism: novel oral anticoagulant delivery systems.
Despite intensive research in the field of oral anticoagulants over the last decade, simple and effective long-term prevention of thromboembolism is still an unmet need. In addition to drug discovery approaches, the development of novel oral drug delivery systems (DDSs) of clinically well-established anticoagulants presents an intriguing mean of improvement of anticoagulant therapy. The latter topic is therefore the focus of the present review. All relevant clinical trials with anticoagulants formulated in the oral DDS are reviewed, and selected preclinical examples of promising novel anticoagulant DDSs are also described. For greater understanding, a background on DDS and drug absorption from the gastrointestinal tract is also provided. Three leading approaches for the oral anticoagulant DDS are currently being investigated in clinical settings, all relying on coadministration of anticoagulants with specific carriers. In contrast to the clinical setting, a diverse range of possibilities for oral delivery of anticoagulant are being investigated in preclinical trials (e.g., nanotechnology), and it would be therefore interesting to examine their performance in clinical trials.
Homar
Miha
M
SDC Slovenia, Lek Pharmaceuticals d.d., Ljubljana, Slovenia.
Cegnar
Mateja
M
Kotnik
Miha
M
Peternel
Luka
L
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D002210:Caprylates / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D013923:Thromboembolism / Q000517:prevention & control*
D000925:Anticoagulants; D002210:Caprylates; D006495:Heparin, Low-Molecular-Weight; C111140:N-(8-(2-hydroxybenzoyl)amino)caprylate